Monaco Asset Management SAM Sells 60,000 Shares of Novavax, Inc. $NVAX

Monaco Asset Management SAM cut its stake in Novavax, Inc. (NASDAQ:NVAX) by 20.7% in the second quarter, HoldingsChannel reports. The fund owned 230,000 shares of the biopharmaceutical company’s stock after selling 60,000 shares during the period. Monaco Asset Management SAM’s holdings in Novavax were worth $1,449,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Bank of New York Mellon Corp increased its holdings in shares of Novavax by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 454,432 shares of the biopharmaceutical company’s stock valued at $2,913,000 after purchasing an additional 17,981 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Novavax in the 1st quarter valued at $290,000. Hussman Strategic Advisors Inc. boosted its position in Novavax by 100.0% in the 1st quarter. Hussman Strategic Advisors Inc. now owns 168,000 shares of the biopharmaceutical company’s stock valued at $1,077,000 after buying an additional 84,000 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Novavax in the 1st quarter valued at $99,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Novavax during the first quarter worth $71,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Down 2.0%

Novavax stock opened at $7.44 on Friday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 3.26, a PEG ratio of 0.12 and a beta of 2.68. The company’s 50 day simple moving average is $8.39 and its 200 day simple moving average is $7.58. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. Novavax, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $11.55.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($0.17). The firm had revenue of $70.45 million during the quarter, compared to analyst estimates of $55.63 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The company’s revenue for the quarter was down 16.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on NVAX. Bank of America reiterated an “underperform” rating and issued a $7.00 price target (down previously from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Wall Street Zen downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald started coverage on shares of Novavax in a research report on Friday, October 24th. They set an “overweight” rating and a $18.00 price target for the company. TD Cowen dropped their price target on shares of Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.71.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.